Vopratelimab is under clinical development by Jounce Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vopratelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vopratelimab (JTX-2011) is under development for the treatment of solid tumors including head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), melanoma, urothelial cancer and gastric cancer. It is administered through intravenous route. The drug candidate acts by targeting the antigen CD278 (ICOS-inducible T-cell costimulator). It is developed based on translational science platform.
Jounce Therapeutics overview
Jounce Therapeutics is a clinical stage immunotherapy company. It develops therapies that enable the immune system to attack tumors. The company’s major pipeline products include Vopratelimab, an IgG1 monoclonal antibody that activates T cells through ICOS; JTX-8064, an LILRB2 inhibitor novel antibody; JTX-1484; target is LILRB4, pimivalimab target receptor is PD-1, GS-1811; target receptor is CCR8. Its discovery programs include LILRB1, treatment of myeloid and lymphoid cancers. Jounce offers services in the areas of tumor immunology, antibody discovery and optimization and integrated translational capabilities. The company has collaborations with the universities, general hospitals, and cancer centers. Jounce Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Vopratelimab’s drug-specific PTSR and LoA scores, buy the report here.